Drug resistance in cancer: principles of emergence and prevention. - Wikidata - wikimedia - TriplyDB

Drug resistance in cancer: principles of emergence and prevention.

Drug resistance in cancer: principles of emergence and prevention.

http://www.wikidata.org/entity/Q33892278

about

Evolutionary dynamics of cancer in response to targeted combination therapy Cancer genome landscapes Optimal treatment and stochastic modeling of heterogeneous tumors Evolutionary rescue: linking theory for conservation and medicine Bioinformatics and systems biology Anti-inflammatory/antioxidant use in long-term maintenance cancer therapy: a new therapeutic approach to disease progression and recurrence How cell death shapes cancer Quantitative modeling of chronic myeloid leukemia: insights from radiobiology Effect of cellular quiescence on the success of targeted CML therapy Evolution of resistance to targeted anti-cancer therapies during continuous and pulsed administration strategies Analysis of compound synergy in high-throughput cellular screens by population-based lifetime modeling Combination of two but not three current targeted drugs can improve therapy of chronic myeloid leukemia Optimizing combination therapies with existing and future CML drugs Fitness conferred by BCR-ABL kinase domain mutations determines the risk of pre-existing resistance in chronic myeloid leukemia Nonheritable cellular variability accelerates the evolutionary processes of cancer Within-host stochastic emergence dynamics of immune-escape mutants Spatial heterogeneity in drug concentrations can facilitate the emergence of resistance to cancer therapy Dose-Dependent Mutation Rates Determine Optimum Erlotinib Dosing Strategies for EGFR Mutant Non-Small Cell Lung Cancer Patients Cancer in light of experimental evolution The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers Translating neoadjuvant therapy into survival benefits: one size does not fit all.Escherichia coli resistance to nonbiocidal antibiofilm polysaccharides is rare and mediated by multiple mutations leading to surface physicochemical modifications Designing a broad-spectrum integrative approach for cancer prevention and treatment.Eradication of chronic myeloid leukemia stem cells: a novel mathematical model predicts no therapeutic benefit of adding G-CSF to imatinib Strategic treatment interruptions during imatinib treatment of chronic myelogenous leukemia.Dynamics and potential impact of the immune response to chronic myelogenous leukemia Rational design of non-resistant targeted cancer therapies Mathematical models of the transitions between endocrine therapy responsive and resistant states in breast cancer.Evolution of acquired resistance to anti-cancer therapy.Targeting the Achilles heel of multidrug-resistant cancer by exploiting the fitness cost of resistance.Intratumor heterogeneity alters most effective drugs in designed combinations.Evolutionary dynamics of carcinogenesis and why targeted therapy does not work.Role of symmetric and asymmetric division of stem cells in developing drug resistance.Genomic mutation rates: what high-throughput methods can tell us What does physics have to do with cancer?Evolution of ibrutinib resistance in chronic lymphocytic leukemia (CLL)Error-prone translesion synthesis mediates acquired chemoresistance Relapse of acute promyelocytic leukemia with PML-RARalpha mutant subclones independent of proximate all-trans retinoic acid selection pressure Timing and heterogeneity of mutations associated with drug resistance in metastatic cancers Dynamics of mutant BCR-ABL-positive clones after cessation of tyrosine kinase inhibitor therapy.

P2860

Q21128788-E2C66CA9-08D5-4700-8D56-ABA208BE2973 Q22242276-8C476A68-14C6-49B4-89ED-67674AE6565D Q26739901-4732E201-77D7-4599-AA82-8FED6A2E0C28 Q26862297-E093ACAC-2F8C-44F8-86E0-85109A928D9B Q27005417-5AF476F4-295E-424E-AA14-1AED80C73449 Q27010314-D4035F04-BDBD-4A42-8FD9-363D64DFD697 Q27021441-924DD82F-4528-4BD5-AB6A-44C0A7A1B5BF Q28384954-D5C25930-30FA-4C15-8D65-81CA61BF77C0 Q28469312-7BCB08E7-91DB-44D4-8B5C-920B9CAAB8BB Q28471733-714CBA13-0750-4ACA-9043-378483A177F0 Q28472663-97EE7490-B672-4CDF-8199-BBFBBE8D8A7E Q28474737-6C96A4E4-FA45-4023-87AA-0EE832C66449 Q28475255-F6BE3454-77F9-491B-B3C1-8E12547C57B3 Q28478165-DFE4F163-B89C-4EB8-AAB7-6F40AD239BB6 Q28482084-9CE01274-DD40-4DFD-8B82-025C8DCCFC3C Q28544655-A27691DD-A153-4552-A6D4-2638155365C6 Q28544732-F6353C0D-6A51-41D9-ABF9-DC8EE170A0B5 Q28550661-037DB8A2-BD91-4BA2-B64A-1AD9F7AA17BE Q28727500-7A73E70D-AC7E-43D4-B920-8B3B121B5A67 Q29395525-92D474FD-B297-4AD8-9A2E-299D17E631C8 Q30251738-D1C6E8F5-68EC-413E-AE83-FD43EAFC2E13 Q30541729-F680AB3F-8BD2-46F2-BAF6-C4EC9466B348 Q30736359-8B06068B-D840-4BE1-BC8C-D4C0B23ACD36 Q30873646-4E876253-DAB0-42E4-88A2-27AF8041DBEC Q30984215-3CF00C86-EA60-4938-B318-0F507405636C Q33345245-DBB812E3-19AB-4B4D-B50C-738BCA856FFC Q33594692-2E9B6266-7C34-4C63-B187-7880CF6A14E0 Q33656026-25BF47E8-FACC-416F-92FF-A9415B2CD65F Q33758382-3C9E4005-EBE8-4909-8F37-018665EBBDD4 Q33763765-F7C06E05-5DD8-44F7-AEAB-BB9B4C2D421E Q33972115-00CC98D6-E8F5-4B79-A24F-CC53DAFF2183 Q34005286-270C11DE-4337-4971-9378-D8B29760D3B5 Q34165690-EF7BA2E3-FD40-4C37-B142-7AFB0245FF66 Q34187406-6E8A4522-B4D7-4C1E-B743-616010A39361 Q34208808-5060EEF4-7D0D-4242-AEFD-F941B676E76C Q34280885-879AD9F1-EA55-456C-A2E8-74672E301CDF Q34376054-4FB1474A-7B78-4406-BAA8-189AAE29267C Q34471149-3A16C7B6-A1A7-4E14-86F4-D86606A24753 Q34525966-EF13A702-F340-4587-ABBD-AC940D67020F Q34612579-31140C48-D9F4-442D-8E19-536CADFDD548

P2860

Drug resistance in cancer: principles of emergence and prevention.

http://www.wikidata.org/entity/Q33892278

description

2005 nî lūn-bûn

@nan

2005 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2005 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

name

Drug resistance in cancer: principles of emergence and prevention.

@ast

Drug resistance in cancer: principles of emergence and prevention.

@en

type

label

Drug resistance in cancer: principles of emergence and prevention.

@ast

Drug resistance in cancer: principles of emergence and prevention.

@en

prefLabel

Drug resistance in cancer: principles of emergence and prevention.

@ast

Drug resistance in cancer: principles of emergence and prevention.

@en

P1433

Q33892278-09AC1A1F-0378-48C0-AD28-9B9F4F776031

P1476

Q33892278-16FFA8D2-576C-4960-AF10-0E79F41EEA3A

P2093

Q33892278-AC1E41C2-0EE6-4CA1-80AF-F19F726BC912

Q33892278-CD092CF2-FCD8-4642-8551-238C350EF32F

P2860

Q33892278-04C29FE9-2400-4E6A-8764-8752DA261E09

Q33892278-069CA621-A45E-4D2C-845B-319B59C80F0D

Q33892278-1782450D-A158-44BA-B79D-A5F84DB2F8E7

Q33892278-227659DC-9876-43FD-B738-A5A45D690BBC

Q33892278-2827ED14-E30F-4FFA-A9E0-6885ECCF5CBB

Q33892278-2FB8023D-242F-49BE-AF8D-199BFE6DE37E

Q33892278-35B7A880-88CC-43C4-A2D7-B6E9FC47CBE5

Q33892278-48ED4A2F-71F9-4AE5-BF99-B41F612EB943

Q33892278-4BAB5B94-BDC6-4BEB-8FF4-FB4202F4213C

Q33892278-6665D4D0-45A8-413E-BA6D-FD380172B6D5

P304

Q33892278-F289143E-26E8-4C19-84AD-0F1658CC6A7A

P31

Q33892278-C2A3006C-07ED-4803-AC31-3FD4620A2F02

P356

Q33892278-2F5125DC-B581-4A80-9791-5FC2B242B5AE

P407

Q33892278-97FDE29C-8B88-47A6-BC24-C22751A994F5

P433

Q33892278-1683E61A-B97B-4E56-B962-F0F805B07102

P478

Q33892278-A482E302-C3D8-4689-A3F3-6CBC27A1EECF

P577

Q33892278-1D4EF2D1-0886-4DDA-9D39-39BC6BCD6AAC

P5875

Q33892278-6EA864AE-3128-46B4-B982-FC75C901FCAD

P698

Q33892278-B139F8DC-F2B8-46A7-9B9D-0D72E7475095

P932

Q33892278-729F6E3F-7614-420B-98F9-09C68914E741

P356

PNAS.0501870102

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Drug resistance in cancer: principles of emergence and prevention.

@en

P2093

Dominik Wodarz

http://www.w3.org/2001/XMLSchema#string

Natalia L Komarova

http://www.w3.org/2001/XMLSchema#string

P2860

cis-Dichlorodiammineplatinum(II): combination chemotherapy and cross-resistance studies with tumors of mice

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

Overriding imatinib resistance with a novel ABL kinase inhibitor

Chronic myelogenous leukemia: biology and therapy.

Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistance.

STI-571 must select for drug-resistant cells but 'no cell breathes fire out of its nostrils like a dragon'.

Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias.

Chronic myeloid leukemia--advances in biology and new approaches to treatment.

Mechanisms and implications of imatinib resistance mutations in BCR-ABL.

Differences in the rates of gene amplification in nontumorigenic and tumorigenic cell lines as measured by Luria-Delbrück fluctuation analysis.

P304

9714-9719

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.0501870102

http://www.w3.org/2001/XMLSchema#string

P407

P433

27

http://www.w3.org/2001/XMLSchema#string

P478

102

http://www.w3.org/2001/XMLSchema#string

P577

2005-06-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7763968

http://www.w3.org/2001/XMLSchema#string

P698

15980154

http://www.w3.org/2001/XMLSchema#string

P932

1172248

http://www.w3.org/2001/XMLSchema#string